

Portfolio of Investments

| Investments in Securities | Coupon % | Maturity | Shares/Par | Value (\$) | % of Net Assets |
|-------------------------------|----------|----------|------------|-------------|-----------------|
| 10X Genomics | | | 424,022 | 60,041,515 | 0.344% |
| AbbVie | | | 2,842,775 | 304,603,341 | 1.747% |
| Abcam | | | 1,350,398 | 28,463,443 | 0.163% |
| ACADIA Pharmaceuticals | | | 1,907,376 | 101,968,321 | 0.585% |
| Accelaron Pharma | | | 1,422,608 | 182,008,468 | 1.044% |
| Adaptive Biotechnologies | | | 670,823 | 39,665,764 | 0.228% |
| Adverum Biotechnologies | | | 717,020 | 7,772,497 | 0.045% |
| Agilent Technologies | | | 2,213,181 | 262,239,817 | 1.504% |
| Agios Pharmaceuticals | | | 479,006 | 20,755,330 | 0.119% |
| Akero therapeutics | | | 264,727 | 6,829,957 | 0.039% |
| Alcon | | | 582,022 | 38,644,017 | 0.222% |
| Alexion Pharmaceuticals | | | 298,906 | 46,701,073 | 0.268% |
| Alkermes | | | 79,307 | 1,582,175 | 0.009% |
| Allogene therapeutics | | | 942,935 | 23,799,679 | 0.137% |
| Alnylam Pharmaceuticals | | | 943,357 | 122,608,109 | 0.703% |
| Amarin, ADR | | | 1,011,343 | 4,945,467 | 0.028% |
| Amedisys | | | 196,515 | 57,643,745 | 0.331% |
| Amgen | | | 911,171 | 209,496,436 | 1.202% |
| Anthem | | | 813,000 | 261,046,170 | 1.497% |
| Apellis Pharmaceuticals | | | 919,830 | 52,614,276 | 0.302% |
| Ardelyx | | | 1,099,472 | 7,113,584 | 0.041% |
| Argenx, ADR | | | 735,941 | 216,432,889 | 1.242% |
| Arvinas | | | 616,199 | 52,333,781 | 0.300% |
| Ascendis Pharma, ADR | | | 875,500 | 146,015,890 | 0.838% |
| Astellas Pharma | | | 2,574,200 | 39,858,295 | 0.229% |
| AstraZeneca, ADR | | | 5,013,119 | 250,605,819 | 1.438% |
| Atea Pharmaceuticals | | | 207,250 | 8,658,905 | 0.050% |
| Atea Pharmaceuticals | | | 1,209,613 | 48,010,750 | 0.275% |
| Atricure | | | 440,846 | 24,541,897 | 0.141% |
| Avantor | | | 3,431,763 | 96,604,128 | 0.554% |
| Axsome therapeutics | | | 371,518 | 30,267,571 | 0.174% |
| Becton, Dickinson & Company | | | 1,272,122 | 318,310,367 | 1.826% |
| BeiGene, ADR | | | 375,850 | 97,115,882 | 0.557% |
| Biogen | | | 660,881 | 161,823,322 | 0.928% |
| BioMarin Pharmaceutical | | | 494,374 | 43,351,656 | 0.249% |
| BioNTech, ADR | | | 1,177,647 | 96,001,783 | 0.551% |
| Bluebird Bio | | | 272,880 | 11,807,518 | 0.068% |
| Blueprint Medicines | | | 575,916 | 64,588,979 | 0.371% |
| Bristol-Myers Squibb | | | 5,090,748 | 3,513,125 | 0.020% |
| Bruker | | | 1,874,415 | 101,462,084 | 0.582% |
| Burning Rock Biotech, ADR | | | 589,186 | 13,610,197 | 0.078% |
| C4 therapeutics | | | 227,135 | 7,524,983 | 0.043% |
| C4 therapeutics | | | 676,992 | 21,307,308 | 0.122% |
| Cara Therapeutics | | | 634,496 | 9,599,924 | 0.055% |
| Catalent | | | 741,973 | 77,217,130 | 0.443% |
| Centene | | | 4,463,916 | 267,968,877 | 1.537% |
| Cerevel therapeutics Holdings | | | 190,090 | 1,074,009 | 0.006% |
| Cerevel therapeutics Holdings | | | 555,303 | 9,206,924 | 0.053% |
| Cerevel therapeutics Holdings | | | 722,411 | 11,378,696 | 0.065% |
| Chugai Pharmaceutical | | | 942,500 | 50,287,223 | 0.288% |
| Cigna | | | 1,445,293 | 300,881,097 | 1.726% |
| Constellation Pharmaceuticals | | | 193,283 | 5,566,550 | 0.032% |
| Cooper Companies | | | 207,212 | 75,284,264 | 0.432% |
| Crispr therapeutics | | | 366,368 | 56,094,604 | 0.322% |
| Curevac | | | 383,340 | 31,077,374 | 0.178% |
| Daiichi Sankyo | | | 2,922,300 | 100,147,799 | 0.574% |
| Danaher | | | 2,103,092 | 467,180,857 | 2.680% |
| Deciphera Pharmaceuticals | | | 285,290 | 16,281,500 | 0.093% |
| Denali therapeutics | | | 1,775,283 | 148,697,704 | 0.853% |
| Dexcom | | | 344,044 | 127,199,948 | 0.730% |
| DiaSorin | | | 229,760 | 47,971,757 | 0.275% |
| Dicerna Pharmaceuticals | | | 734,448 | 16,179,889 | 0.093% |
| Eisai | | | 449,600 | 32,152,334 | 0.184% |
| Elanco Animal Health | | | 1,021,155 | 31,318,824 | 0.180% |
| Eli Lilly And | | | 2,767,268 | 467,225,529 | 2.680% |

| | | | |
|-------------------------------------|-----------|-------------|--------|
| Enanta Pharmaceuticals | 245,064 | 10,317,194 | 0.059% |
| Envista Holdings | 2,746,597 | 92,642,717 | 0.531% |
| Epizyme | 561,048 | 6,092,981 | 0.035% |
| Evotec | 817,752 | 30,217,475 | 0.173% |
| Exact Sciences | 1,313,962 | 174,086,825 | 0.999% |
| Exelixis | 5,360,713 | 107,589,510 | 0.617% |
| Fate Therapeutics | 1,182,440 | 107,519,269 | 0.617% |
| FibroGen | 1,053,397 | 39,070,495 | 0.224% |
| G1 therapeutics | 192,276 | 3,459,045 | 0.020% |
| Generation Bio | 1,086,090 | 30,790,652 | 0.177% |
| Genmab | 133,381 | 54,085,184 | 0.310% |
| GenMark Diagnostics | 1,287,532 | 18,797,967 | 0.108% |
| Global Blood Therapeutics | 540,256 | 23,398,487 | 0.134% |
| Guardant Health | 554,082 | 71,410,088 | 0.410% |
| GW Pharmaceuticals, ADR | 194,362 | 22,431,318 | 0.129% |
| HCA Healthcare | 1,272,016 | 209,195,751 | 1.200% |
| Health Sciences Acquisitions Corp 2 | 691,234 | 8,854,708 | 0.051% |
| Hologic | 2,745,451 | 199,951,196 | 1.147% |
| Homology Medicines | 311,377 | 3,515,446 | 0.020% |
| Humana | 769,312 | 315,625,634 | 1.811% |
| ICU Medical | 150,194 | 32,215,111 | 0.185% |
| IGM Biosciences | 265,053 | 23,401,529 | 0.134% |
| Incyte | 2,639,803 | 229,610,065 | 1.317% |
| Insmed | 1,655,714 | 55,118,719 | 0.316% |
| Insulet | 324,035 | 82,833,067 | 0.475% |
| Intuitive Surgical | 772,892 | 632,302,945 | 3.627% |
| Ionis Pharmaceuticals | 1,731,877 | 97,920,326 | 0.562% |
| Iovance Biotherapeutics | 2,509,660 | 116,448,224 | 0.668% |
| Ipsen | 225,377 | 18,636,021 | 0.107% |
| iRhythm Technologies | 361,048 | 85,644,196 | 0.491% |
| Karuna therapeutics | 393,563 | 39,982,065 | 0.229% |
| Karyopharm Therapeutics | 404,145 | 6,256,165 | 0.036% |
| Kodiak Sciences | 1,052,221 | 154,581,787 | 0.887% |
| Kronos Bio | 377,354 | 11,271,564 | 0.065% |
| Kronos Bio | 321,236 | 9,115,553 | 0.052% |
| Lantheus Holdings | 953,644 | 12,864,658 | 0.074% |
| Lonza Group | 76,838 | 49,496,489 | 0.284% |
| Merck | 520,073 | 89,200,038 | 0.512% |
| Merck | 6,020,440 | 492,471,992 | 2.825% |
| Mettler-Toledo International | 46,517 | 53,014,495 | 0.304% |
| Milestone Pharmaceuticals | 284,463 | 1,905,902 | 0.011% |
| Mirati Therapeutics | 469,054 | 103,023,021 | 0.591% |
| Moderna therapeutics | 936,291 | 97,814,321 | 0.561% |
| Molina Healthcare | 620,885 | 132,049,822 | 0.758% |
| Morphosys | 167,774 | 19,616,044 | 0.113% |
| Neurocrine Biosciences | 1,017,221 | 97,500,633 | 0.559% |
| Nevro | 528,410 | 91,467,771 | 0.525% |
| Novocure | 422,946 | 73,186,576 | 0.420% |
| Option Care Health | 647,887 | 10,132,953 | 0.058% |
| Outset Medical | 190,164 | 10,808,922 | 0.062% |
| Outset Medical | 1,576,961 | 85,152,740 | 0.488% |
| Pacific Biosciences of California | 2,607,301 | 67,633,388 | 0.388% |
| Pennant | 572,781 | 33,255,665 | 0.191% |
| Penumbra | 578,552 | 101,246,600 | 0.581% |
| Phreesia | 695,190 | 37,721,009 | 0.216% |
| PPD | 673,065 | 23,032,284 | 0.132% |
| PRA Health Sciences | 393,654 | 49,379,958 | 0.283% |
| Prelude therapeutics | 311,538 | 22,290,544 | 0.128% |
| Progenics Pharmaceuticals | 842,223 | 0 | 0.000% |
| PTC Therapeutics | 439,659 | 26,832,389 | 0.154% |
| Quanterix | 747,505 | 34,758,983 | 0.199% |
| Quidel | 508,505 | 91,352,923 | 0.524% |
| Radius Health | 151,205 | 2,700,521 | 0.015% |
| RAPT therapeutics | 623,614 | 12,316,377 | 0.071% |
| Reata Pharmaceuticals | 219,796 | 27,171,182 | 0.156% |
| Regeneron Pharmaceuticals | 480,308 | 232,041,598 | 1.331% |
| REGENXBIO | 217,220 | 9,853,099 | 0.057% |
| Roche Holding | 512,022 | 178,336,528 | 1.023% |
| Rocket Pharmaceuticals | 1,066,942 | 58,511,099 | 0.336% |
| Royalty Pharma | 884,428 | 44,265,621 | 0.254% |
| Royalty Pharma | 1,066,300 | 53,368,315 | 0.306% |
| SAGE Therapeutics | 738,854 | 63,918,260 | 0.367% |

| | | | | |
|--|------|-----------|-----------------------|--------|
| Sanofi | | 863,398 | 83,683,137 | 0.480% |
| Sarepta Therapeutics | | 449,034 | 76,555,807 | 0.439% |
| Sartorius | | 201,984 | 85,071,543 | 0.488% |
| Scholar Rock Holding | | 677,703 | 32,888,927 | 0.189% |
| Seagen | | 1,182,679 | 207,134,400 | 1.188% |
| Seer | | 2,567,550 | 136,935,144 | 0.786% |
| Shockwave Medical | | 918,475 | 95,264,227 | 0.546% |
| Stoke therapeutics | | 436,534 | 27,034,551 | 0.155% |
| Stryker | | 1,706,747 | 418,221,285 | 2.399% |
| Tandem Diabetes Care | | 475,175 | 45,464,744 | 0.261% |
| Teleflex | | 323,390 | 133,097,622 | 0.764% |
| Thermo Fisher Scientific | | 1,393,481 | 649,055,580 | 3.723% |
| Thrive Earlier Detection | | 3,442,748 | 18,501,672 | 0.106% |
| Translate Bio | | 816,367 | 15,045,644 | 0.086% |
| TRP Government Reserve | 0.08 | 6,500,507 | 6,500,507 | 0.037% |
| Turning Point therapeutics | | 463,281 | 56,450,790 | 0.324% |
| Twist Bioscience | | 423,067 | 59,775,136 | 0.343% |
| Ultragenyx Pharmaceutical | | 1,328,562 | 183,912,838 | 1.055% |
| Uniqure | | 568,699 | 20,547,095 | 0.118% |
| UnitedHealth Group | | 2,915,787 | 1,022,508,185 | 5.866% |
| Veeva Systems | | 423,312 | 115,246,692 | 0.661% |
| Vertex Pharmaceuticals | | 1,854,663 | 438,331,053 | 2.514% |
| WaVe Life Sciences | | 561,271 | 4,417,203 | 0.025% |
| West Pharmaceutical Services | | 529,235 | 149,937,568 | 0.860% |
| WuXi Biologics | | 2,957,500 | 39,220,425 | 0.225% |
| Xencor | | 979,546 | 42,737,592 | 0.245% |
| Zai Lab, ADR | | 288,352 | 39,025,560 | 0.224% |
| Zimmer Biomet Holdings | | 311,750 | 48,037,558 | 0.276% |
| Zymeworks | | 367,345 | 17,360,725 | 0.100% |
| Miscellaneous Securities ‡ | | | 1,335,874,974 | |
| Total Investments in Securities | | | 17,362,203,304 | |

‡ At the discretion of the advisor, the identity of certain securities has been concealed to protect the fund's interests.

NET ASSETS

17,432,311,412

NET ASSET VALUE PER SHARE

Health Sciences Fund Shares

98.85

(\$15,752,873,631 / 159,359,814 Shares Outstanding)

Health Sciences Fund - I Class Shares

98.87

(\$1,679,437,781 / 16,986,630 Shares Outstanding)

| | |
|-------|--|
| ADR | American Depositary Receipts |
| ADS | American Depositary Shares |
| AR | Auction Rate security with an interest rate reset feature through a modified Dutch auction at predetermined short-term intervals; rate shown is effective rate at period end |
| ARM | Adjustable Rate Mortgage |
| BAN | Bond Anticipation Note |
| CDA | Community Development Administration |
| CLN | Credit Linked Note |
| CMO | Collateralized Mortgage Obligation |
| COP | Certificate of Participation |
| DOT | Department of Transportation |
| EFA | Educational Facility Authority |
| ETC | Equipment Trust Certificate |
| FDR | Fiduciary Depository Receipt |
| FRN | Floating Rate Note |
| GDR | Global Depositary Receipts |
| GDS | Global Depositary Shares |
| GO | General Obligation |
| HDA | Housing Development Authority |
| HEFA | Health & Education Facility Authority |
| HFA | Health Facility Authority |
| HFC | Housing Finance Corp |
| HFFA | Health Facility Financing Authority |
| HHEFA | Health & Higher Education Facility Authority |
| IDA | Industrial Development Authority/Agency |
| IDB | Industrial Development Bond |
| IDC | Industrial Development Corp |
| IDRB | Industrial Development Revenue Bond |
| IO | Interest Only security for which the fund receives interest on notional principal (par) |
| PCR | Pollution Control Revenue |
| PFA | Public Finance Authority |
| PIK | Payment-in-kind |
| PTC | Pass-Through Certificate |
| RAC | Revenue Anticipation Certificate |
| RAN | Revenue Anticipation Note |
| RAW | Revenue Anticipation Warrant |
| REIT | Real Estate Investment Trust |

RIB Residual interest bond issued by a third party securitization trust and purchased directly through a cash transaction that involved no exchange of previously held securities; rate varies inversely to short-term rates and the rate presented is the effective rate at period-end
STEP Stepped coupon bond for which the coupon rate of interest will adjust on specified future dates(s)
TAN Tax Anticipation Note
TAW Tax Anticipation Warrant
TBA To Be Announced purchase commitment
TDFA Trade & Deposit Facility Agreement
TECP Tax-Exempt Commercial Paper
TRAN Tax Revenue Anticipation Note
VR Variable Rate; rate shown is effective rate at period end
VRDN Variable Rate Demand Note under which the holder has the right to sell the security to the issuer or the issuer's agent at a predetermined price (generally par) on specified dates upon required notification; rate shown is effective rate at period-end

Important Information

The portfolio data contained herein is for informational purposes only and does not constitute a recommendation or an offer for a particular security or investment. Unlike the fund's regulatory filings, the portfolio data and its presentation in this document do not conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. The holdings are not audited and the information may differ in certain respects, such as derivatives exposure and security name, from the information found in the complete list of portfolio investments in the semiannual and annual shareholder reports and Form N-Q.